Results 161 to 170 of about 24,524 (277)

Cardiorenal Outcomes of Dapagliflozin vs. Empagliflozin in Advanced Chronic Kidney Disease and Diabetes

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 168-177, July 2026.
Target trial emulation of a multi‐institutional electronic health record network showed comparable cardiorenal effectiveness and safety of dapagliflozin versus empagliflozin in adults with type 2 diabetes and advanced‐stage chronic kidney disease.
Shih‐Hsuan Lin, Jia‐Jin Chen, Ching‐Chung Hsiao, Yu‐Wei Fang, Meng‐Ting Chen, Ming‐Hsien Tsai, Huang‐Yu Yang   +6 more
wiley   +1 more source

Comparative safety of sulfonylurea therapies on cardiovascular and severe hypoglycemia outcomes among adults with type 2 diabetes and moderate cardiovascular risk: a target trial emulation. [PDF]

BMJ Open Diabetes Res Care
Sklepinski S, Ratzki-Leewing AA, Herrin J, Swarna KS, Deng Y, Polley EC, Neumiller JJ, Galindo RJ, Umpierrez GE, Ross JS, Brito JP, Montori VM, Borah BJ, Maron BA, Mickelson MM, McCoy RG.   +15 more
europepmc   +1 more source

Long‐Term Glycemic and Metabolic Profiles Observed During Imeglimin Therapy in Japanese Patients With Type 2 Diabetes Mellitus

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 4, July 2026.
In a real‐world setting, 12‐month imeglimin therapy in Japanese patients with type 2 diabetes provided sustained glycemic improvements and enhanced endogenous insulin secretion. Importantly, these durable metabolic benefits were achieved without requiring an increase in overall glucose‐lowering treatment intensity.
Yohei Fujita, Shuji Suganami, Yuka Morita, Toshio Matsui, Masahisa Hata, Masahiro Hatazaki   +5 more
wiley   +1 more source

Continuous glucose monitoring-based evaluation of percentage coefficient of variation (%CV) as a metric of intraday glycemic variability in South India. [PDF]

Sci Rep
Hussain MA, Kumar H A, Lingaiah M.
europepmc   +1 more source

Can a Lifestyle‐Centred, Low‐Dose Model Improve Hypertension and Diabetes Care in Low‐ and Middle‐Income Countries? Real‐World Implementation Data From Zambia

Lifestyle Medicine, Volume 7, Issue 3, July 2026.
ABSTRACT Introduction Hypertension and Type 2 diabetes are major contributors to the growing burden of non‐communicable diseases in rural Zambia. Lifestyle interventions are central to prevention and management, yet implementation remains limited in resource‐constrained settings.
Keith Birrell, Ginny Birrell, Fastone Goma   +2 more
wiley   +1 more source

Glucagon-like peptide 1 receptor agonist discontinuation and risks of major adverse cardiovascular events in adults with type 2 diabetes: target trial emulation. [PDF]

BMJ Med
Xie Y, Choi T, Al-Aly Z.
europepmc   +1 more source

A Systematic Review and Expert Evaluation of Perioperative SGLT2 Inhibitor‐Associated Ketoacidosis Case Reports

Acta Anaesthesiologica Scandinavica, Volume 70, Issue 6, July 2026.
ABSTRACT Introduction The use of sodium–glucose cotransporter‐2 inhibitors (SGLT2i) in the perioperative setting may lead to SGLT2i‐associated postoperative ketoacidosis (SAPKA) in patients with type 2 diabetes (T2D). Therefore, cessation of this drug is recommended before surgery.
L. I. P. Snel, X. Li, F. Jamaludin, S. E. Siegelaar, F. Holleman, T. M. Vriesendorp, J. H. DeVries, J. B. L. Hoekstra, B. Preckel, D. H. van Raalte, J. Hermanides, A. H. Hulst   +11 more
wiley   +1 more source

Five-year follow-up of incretin-based therapy in a patient with KCNJ11-related permanent neonatal diabetes: Achieving insulin discontinuation and sulfonylurea reduction. [PDF]

J Diabetes Investig
Ohkuma T, Aotani R, Sakamoto W, Oshiro A, Ago T.   +4 more
europepmc   +1 more source

Efficacy and safety of switching to iGlarLixi from premixed insulin therapy in patients with type 2 diabetes: A real‐world experience

Diabetic Medicine, Volume 43, Issue 7, July 2026.
Abstract Aims Fixed‐ratio combinations such as iGlarLixi are recommended over premixed insulin as first‐line injectable therapy for type 2 diabetes mellitus (T2DM), yet real‐world evidence on transitions from premix to iGlarLixi remains limited. This study aimed to evaluate the efficacy and safety of switching from premixed insulin to iGlarLixi in a ...
Chun‐Jui Huang, Shun‐Jie Yang, Cheng‐Pin Cheng, Chun‐Hsing Lin, Ya‐Chun Lee, Harn‐Shen Chen   +5 more
wiley   +1 more source

Understanding Diabetes Distress: A Study of Contributing Factors Among Adults With Type 2 Diabetes in Rural East Godavari, Andhra Pradesh. [PDF]

Cureus
Meka RJ, Sundaram M S, Rani K S G, Mani V, Natrajan M.   +4 more
europepmc   +1 more source